TGF-beta2 suppression by the antisense oligonucleotide AP 12009 as therapy for high-grade glioma: safety and efficacy results of phase I/II clinical studies

Autor:	R. Schlingensiepen, M. Mehdorn, J. Schlaier, M. Weller, J. Pichler, Wolfgang Grisold, D. Freudenstein, Ulrich Bogdahn, M. Kunst, G. Stauder, Thomas Hundsberger, L. Spitznagel, Dorothee Koch, G. Wurm, H. Kostron, K. H. Schlingensiepen, M. Winking, Jürgen Meixensberger, M. Goldbrunner, Peter Hau, G. Schackert, H. Wassmann, T. Schneider, G. Stockhammer, S. Schmaus, A. Brawanski
Rok vydání:	2004
Předmět:	Phase i ii business.industry Antisense oligonucleotides Medicine Neurology (clinical) Pharmacology business High-Grade Glioma Transforming growth factor
Zdroj:	Aktuelle Neurologie. 31
ISSN:	1438-9428 0302-4350
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7a014f0378a6352af60dd4cadfd35177 https://doi.org/10.1055/s-2004-832961 Zobrazit plný text záznamu